YOLFTbeta
68

Kontour (Xi'an) Medical Technology Co. Ltd.

688314 · SHG · Healthcare / Medical Devices

25.97CNY-0.89 (-3.31%)

Price History

Full chart

Market Stats

Previous Close26.86
Open26.93
Day Range25.94 – 27.07
52-Week Range27.86 – 57.89
Volume865.17K
Market Cap2.47B
P/E (TTM)29.04
Forward P/E0.00
EPS1.04
Dividend Yield1.56%
Beta-0.05
50-Day Avg31.63
200-Day Avg38.35

About

Kontour (Xi'an) Medical Technology Co., Ltd. engages in the research and development, production, and sale of Class III implantable medical devices in China. The company offers products in the fields of neurosurgery cranial repair and fixation, cardiothoracic surgery sternum fixation, and maxillofacial repair. It also provides oral bone repair materials, oral absorbable biofilm, implant system, and other tools. In addition, the company offers repair and fixation products that include traditional titanium materials, high-end PEEK materials, and absorbent polymer materials; PEEK4D bioactive plates; PEEK bone plates, titanium mesh plates, PEEK link plates, PEEK screws, titanium link plates, test molds, bone plugs, bone mesh, bone plug strips, disposable brain drainage devices, supporting surgical tools, and other complete products for skull repair and fixation surgery process. Kontour (Xi'an) Medical Technology Co., Ltd. was founded in 2005 and is based in Xi'an, China.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Hailong Zhu
  • Employees418
  • HeadquartersNo. 1451, West Section of Biyuan 1st Road, Xi'an, China, 710065, China
  • Websitehttps://www.kontourmedical.com

Leadership

  • Mr. Hailong ZhuGM & Director · b. 1976
  • Mr. Liang ShenChief Financial Officer · b. 1979
  • Mr. Ruoyu ZhaoDirector & Deputy GM · b. 1978
  • Ms. You WuDeputy GM & Director · b. 1982
  • Ms. Huan ZhouBoard Secretary · b. 1988
  • Ming DuAccounting Supervisor
  • Ms. Wei Wei ShangDeputy General Manager · b. 1980

Financials

Income Statement

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue72.49M109.50M147.80M164.08M212.55M239.95M275.03M321.95M349.60M
Growth (%)-+51.07%+34.98%+11.01%+29.54%+12.89%+14.62%+17.06%+8.59%
Cost of Revenue22.54M26.82M31.83M32.16M41.99M50.19M60.38M67.93M74.82M
Gross Profit49.94M82.68M115.98M131.92M170.56M189.76M214.65M254.01M349.60M
Gross Margin68.90%75.51%78.47%80.40%80.25%79.08%78.05%78.90%100.00%
Operating Expense38.31M59.27M55.75M80.11M84.23M103.42M123.21M148.30M238.62M
Operating Income11.63M23.41M60.23M51.80M86.32M86.33M91.43M105.71M110.98M
Operating Margin16.05%21.38%40.75%31.57%40.61%35.98%33.25%32.84%31.74%
EBITDA16.17M29.86M66.19M65.10M103.45M99.69M104.14M119.55M127.02M
EBITDA Margin22.31%27.27%44.78%39.68%48.67%41.55%37.86%37.13%36.33%
Net Income10.06M22.15M51.93M52.38M81.63M75.69M75.51M88.40M98.82M
Net Income Margin13.88%20.23%35.14%31.93%38.40%31.54%27.46%27.46%28.27%
R&D4.41M8.09M10.56M16.90M16.80M18.30M17.64M23.90M25.64M
R&D as % of Total Revenue6.09%7.39%7.15%10.30%7.91%7.63%6.41%7.42%7.34%
Interest Expense96.06K37.27K336.86K564.99K888.91K1.31M2.02M2.31M2.32M
Interest Expense % of Total Revenue0.13%0.03%0.23%0.34%0.42%0.55%0.74%0.72%0.66%

Balance Sheet

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets128.56M155.51M228.32M291.51M573.38M638.14M675.79M747.22M909.16M
Total Liabilities26.66M28.32M35.83M48.46M71.98M96.46M84.31M109.37M185.12M
Total Equity100.01M126.23M192.70M244.53M503.32M543.28M587.18M635.58M717.76M
Cash40.20M20.55M112.05M92.80M325.33M349.24M375.12M378.53M374.07M
Total Debt136.19K3.98M8.12M14.08M23.03M38.94M38.99M44.88M-
Net Debt-40.06M-16.58M-103.93M-78.72M-302.30M-310.30M-336.13M-371.53M-

Cash Flow

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow11.26M22.84M57.78M57.83M103.29M91.98M88.52M140.25M118.04M
Investing Cash Flow4.73M-31.80M19.87M-71.98M-52.74M-28.27M-31.33M-91.36M-
Financing Cash Flow15.39M-11.17M13.82M-4.18M182.49M-41.43M-31.79M-45.95M-
Capital Expenditure985.43K4.05M9.49M72.97M55.24M18.20M14.22M47.40M51.39M
Free Cash Flow10.28M18.78M48.29M-15.15M48.05M73.78M71.00M92.86M66.65M
Dividends Paid20.20K21.65K316.74K330.62K30.17M35.98M31.82M42.70M32.78M
FCF to OCF91.25%82.24%83.57%-26.19%46.52%80.21%80.21%66.21%56.47%
Dividend Paid to FCF0.20%0.12%0.66%-2.18%62.80%48.77%44.82%45.98%49.18%

Earnings

Report DateSep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023
EPS Estimate--------
EPS Actual0.330.240.220.260.320.130.240.24
Surprise--------
Timing--------

Key Statistics & Ratios

Market Cap2.47B
Enterprise Value2.32B
Trailing P/E29.04
Forward P/E0.00
Price / Sales7.01
Price / Book3.48
EPS1.04
Book Value9.31
Revenue (TTM)351.72M
Gross Profit (TTM)271.74M
EBITDA117.32M
Profit Margin24.19%
Operating Margin28.32%
Return on Equity11.66%
Return on Assets7.25%
Shares Outstanding81.63M
Shares Float29.27M
Beta-0.05
Dividend Yield1.56%
Dividend Rate0.47
Payout Ratio50.00%

Dividends

20262×
0.15Sep 16, 20260.32May 13, 2026
20252×
0.20Oct 13, 20250.18May 13, 2025
20242×
0.18Dec 4, 20240.32May 29, 2024
20231×
0.37Apr 27, 2023
20221×
0.44Apr 29, 2022
20211×
0.37Jul 7, 2021

Stock Splits

  • Apr 27, 20231.4:1